All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Aging
    • Biosimilars
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Science '22 in Review
    • Top Biopharma Trends of 2022
    • Top Med-tech Trends of 2022
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • sign in
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, March 23, 2023
Home » Topics » Infection » Coronavirus

Coronavirus
Coronavirus RSS Feed RSS

Vaccine vials and syringe in a martini glass.
Infection

‘22 in review: A toast to the future – of universal vaccines

Dec. 30, 2022
By Mar de Miguel
No Comments
Ice, juice, the exact measure of liquor, a few drops of Angostura... What goes into a good New Year’s Eve cocktail? According to researchers working on vaccines for the most elusive viruses, it will be time soon to toast next-generation vaccines. If 2020 was the year of the COVID-19 pandemic, and in 2021 the year of mRNA vaccinations, 2022 brought polyvalent designs of antigens, evaluated highly neutralizing antibodies, and fine-tuned mRNA technology against SARS-CoV-2, HIV and the flu.
Read More
Globe showing Asia-Pacific region

Top Trends of 2022: Asia Pacific shakes off pandemic isolation, but focus remains on sovereign supply chains, regional deals

Dec. 29, 2022
By Tamra Sami
No Comments
Investment in the fourth quarter of 2022 was dismal in Asia Pacific, as the global venture community focused on preserving capital. And the region faced other challenges throughout the year, as leaders in Australia and across Asia became acutely aware of the vulnerabilities in their supply chains. But the year also saw some big deals and collaborations involving companies across Asia Pacific, along with advances in regenerative and digital medicine.
Read More

In the clinic for Dec. 29, 2022

Dec. 29, 2022
No Comments
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Can-Fite, Junshi, Pfizer.
Read More

Recbio’s COVID-19 vaccine shows strong efficacy in phase II Philippines trial

Dec. 28, 2022
By Doris Yu
No Comments
Jiangsu Recbio Technology Co. Ltd. released phase II data showing its recombinant two-component COVID-19 vaccine Recov appeared more effective than Comirnaty (tozinameran), the mRNA vaccine developed by Biontech SE and Pfizer Inc., as a booster for users of inactivated vaccines.
Read More

Regulatory actions for Dec. 28, 2022

Dec. 28, 2022
No Comments
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Genentech, Intercept, Ipsen, Janux, Kaken, Leo, Mediwound, Mindrank AI, Neuren, Neurocrine, Nova Mentis, Regeneron, Revive, Springworks, Valneva, Zielbio.
Read More

In the clinic for Dec. 28, 2022

Dec. 28, 2022
No Comments
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Acasti, Bioxytran, Can-Fite, Clene, PDS.
Read More
Infection

3C-like proteinase (Mpro) inhibitors described in Pardes Biosciences patent

Dec. 28, 2022
No Comments
Pardes Biosciences Inc. has patented 3C-like proteinase (3CLpro; Mpro; nsp5) inhibitors (particularly HCoV-229E virus and/or SARS-CoV-2 Mpro inhibitors). They are reported to be potentially useful for the treatment of SARS-CoV-2 infections (COVID-19).
Read More

Regulatory actions for Dec. 27, 2022

Dec. 27, 2022
No Comments
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Acer, Adaptimmune, Antengene, Basilea, Biogen, Brainstorm, Celltrion, Coherus, Daiichi Sankyo, DBV, Deka, Disc, Eisai, Elpiscience, Immutep, Junshi, Kite, Relief.
Read More

In the clinic for Dec. 27, 2022

Dec. 27, 2022
No Comments
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Applied Molecular Transport, Atai, Biontech, Cellectis, Dilafor, Immunis, Jiangsu Recbio, Karolinska, Kures, Nanobiotix, Neuren.
Read More
SARS-CoV-2 virus particles
Infection

Genetically attenuated SARS-CoV-2 protects against pneumonia in Syrian hamster model of COVID-19

Dec. 27, 2022
No Comments
Eleven vaccines have now been approved by the World Health Organization for preventing COVID-19, but all exhibit drastically reduced activities after 6 months. Unlike vaccines that express only the spike protein as the immunogen, live attenuated vaccines have the potential to confer a broader and more durable protection.
Read More
Previous 1 2 … 9 10 11 12 13 14 15 16 17 … 502 503 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for March 22, 2023.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for March 22, 2022.
  • Woman with headache

    Nasal spray Zavzpret cleared, Pfizer showing ‘growth on every measure’ in migraine

    BioWorld
    Pricing won’t be known until later for Pfizer Inc.’s Zavzpret (zavegepant), which became the first and only calcitonin gene-related peptide receptor antagonist...
  • Kirill Pevzner and Eran Seger - Protai

    AI drug discovery startup Protai raises $12M in seed funding

    BioWorld
    Artificial intelligence (AI)-powered drug discovery startup Protai Bio Ltd. raised $12 million in additional seed funding, bringing the total amount to $20...
  • Targets with arrows

    Flagship puts $50M toward targeted tissue-homing tech startup

    BioWorld
    In an ideal world, when a patient takes a medicine, it acts only at the specific site of disease in the human body whilst sparing healthy tissues. But it almost...
black cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing